Macquarie Group’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-6,638,910
| Closed | -$24.9M | – | 2069 |
|
|
2024
Q1 | $24.9M | Buy |
6,638,910
+1,667,406
| +34% | +$6.25M | 0.03% | 619 |
|
|
2023
Q4 | $48.8M | Buy |
4,971,504
+723,785
| +17% | +$7.1M | 0.06% | 438 |
|
|
2023
Q3 | $35.5M | Buy |
4,247,719
+173,555
| +4% | +$1.45M | 0.04% | 501 |
|
|
2023
Q2 | $54.2M | Buy |
4,074,164
+60,547
| +2% | +$805K | 0.06% | 403 |
|
|
2023
Q1 | $46.5M | Buy |
4,013,617
+1,093
| +0% | +$12.7K | 0.06% | 442 |
|
|
2022
Q4 | $32.8M | Sell |
4,012,524
-10,748
| -0.3% | -$87.9K | 0.04% | 578 |
|
|
2022
Q3 | $23.4M | Buy |
4,023,272
+48,995
| +1% | +$285K | 0.03% | 650 |
|
|
2022
Q2 | $17.6M | Buy |
3,974,277
+133,251
| +3% | +$589K | 0.02% | 731 |
|
|
2022
Q1 | $35K | Buy |
3,841,026
+1,941,270
| +102% | +$17.7K | 0.03% | 625 |
|
|
2021
Q4 | $38.9M | Buy |
1,899,756
+1,692,396
| +816% | +$34.6M | 0.03% | 579 |
|
|
2021
Q3 | $5.3M | Sell |
207,360
-3,590
| -2% | -$91.7K | ﹤0.01% | 1093 |
|
|
2021
Q2 | $7.38M | Buy |
210,950
+20,743
| +11% | +$725K | 0.01% | 1018 |
|
|
2021
Q1 | $6.34M | Sell |
190,207
-889,419
| -82% | -$29.6M | 0.01% | 849 |
|
|
2020
Q4 | $28M | Buy |
1,079,626
+1,077,750
| +57,449% | +$28M | 0.04% | 438 |
|
|
2020
Q3 | $19K | Hold |
1,876
| – | – | ﹤0.01% | 2174 |
|
|
2020
Q2 | $6K | Buy |
+1,876
| New | +$6K | ﹤0.01% | 2329 |
|
|
2016
Q4 | – | Sell |
-316,779
| Closed | -$2.84M | – | 1572 |
|
|
2016
Q3 | $2.84M | Sell |
316,779
-316,871
| -50% | -$2.84M | 0.01% | 863 |
|
|
2016
Q2 | $4.46M | Buy |
+633,650
| New | +$4.46M | ﹤0.01% | 902 |
|